Slingshot members are tracking this corporate initiative:
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool
Do you think this event is important to the companies below? How will it affect their stock price?
Together with tau tangles, the presence of amyloid in the brain is a key marker of Alzheimer's disease, a condition with no cure that is estimated to impact more than 7.4 million Americans by 2025.1 Improving the ability of practicing clinicians to detect evidence of amyloid is an important step in being able to effectively manage the disease. Currently, healthcare providers can find evidence of amyloid in the living brain through two methods: a cerebrospinal fluid (CSF) test and an amyloid brain positron emission tomography (PET) scan.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jan 27, 2016 Projected Implementation: Q1, 2016 Relevance Tracked Until: Q1, 2017
Don’t see a project related to the strategic initiative you care about?
Related Keywords Cerebrospinal Fluid Assay, Amyloid-beta 1-42